Efalizumab

American Journal of Clinical Dermatology

Volumn 6, Issue 2, 2005, Pages 113-118

  Wellington, Keri ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFALIZUMAB; PLACEBO;

ADULT; AGED; ARTHRITIS; BINDING AFFINITY; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL CARCINOMA; HEADACHE; HUMAN; INFLAMMATION; LEUKOCYTE MIGRATION; LONG TERM CARE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MYALGIA; PAIN; PRIORITY JOURNAL; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SHORT COURSE THERAPY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD11A; DRUG ADMINISTRATION SCHEDULE; HUMANS; PSORIASIS;

EID: 17244381086     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200506020-00006     Document Type: Review

References (21)

1. Cather JC, Cather JC, Menter A. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther 2003 Apr; 3 (2): 361-70
2. Lebwohl M. Psoriasis. Lancet 2003; 361: 1197-204
3. Pariser DM. Management of moderate to severe plaque psoriasis with biologic therapy. Manag Care 2003 Apr; 12 (4): 36-44
4. Agarwal R, Vij N, Katare OP. Biotherapy: a novel approach in the treatment of psoriasis. Drugs Future 2002; 27 (11): 1071-7
5. Sobell JM, Hallas SJ. Systemic therapies for psoriasis: understanding current and newly emerging therapies. Semin Cutan Med Surg 2003; 22 (3): 187-95
6. Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol 2003 Aug; 49 (2 Suppl.): S98-104
7. Prinz JC. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003; 17 (3): 257-70
8. Schön MP, Zollner TM, Boehncke WH. The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders. J Invest Dermatol 2003; 121 (5): 951-62
9. Bauer RJ, Dedrick RL, White ML, et al. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 1999 Aug; 27 (4): 397-420
10. Gottlieb AB, Krueger JG, Wittkowski K, et al. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002 May; 138 (5): 591-600
11. Werther WA, Gonzalez TA, O'Connonr SJ, et al. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding rhesus LFA-1. J Immunol 1996; 157 (11): 4986-95
12. Dedrick RL, Bauer R, Bohmann D, et al. Pharmacokinetics and pharmacodynamics of subcutaneously administered anti-CD11a (hu1124) in psoriasis subjects [abstract no. 505 plus poster]. 59th Annual Meeting American Academy of Dermatology; 2001 Mar 2-7; Washington (DC)
13. Gottlieb A, Krueger JG, Bright R, et al. Effects of administrations of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000 Mar; 42: 428-35
14. Krueger J, Gottlieb A, Miller B, et al. Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking [abstract no. HB9]. J Invest Dermatol 2000 Aug; 115 (2): 333
15. Genetech Inc. Raptiv™ (efalizumab): for injection, subcutaneous [online]. Available from URL: http://www.gene.com/gene/products/information/pdf/ raptivaprescribing.pdf [Accessed 2005 Feb 25]
16. Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005; 52 (3): 425-33
17. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003 Dec 17; 290 (23): 3073-80
18. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003 Nov 20; 349 (21): 2004-13
19. Gottlieb AB, Gordon KB, Lebwohl MG, et al. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004 Nov; 3 (6): 614-24
20. Ashcroft DM, Wan Po AL, Williams HC, et al. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999; 141: 185-91
21. Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005 Jan; 141 (1): 31-8